Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2005

View Archived Issues

AZD-103 enters clinic for Alzheimer's disease

Insmed submits response to iPlex approvable letter

InterMune updates status of IPF programs for pirfenidone and Actimmune

Schering AG and Sonus sign agreement for Tocosol Paclitaxel

Obesity drug AOD-9604 begins new phase IIb study

TB Alliance and Bayer team up to study moxifloxacin for TB

Private placement raises funds to support development of Tigris' A-007

EGEN-001 studied in phase I trial for ovarian cancer

DDP-225 begins phase II trial for diarrhea-predominant IBS

AG-707 begins phase I trial for genital herpes

First patients enrolled in IRX-2 phase II head and neck cancer trial

Topigen advances ASM-8 into phase II for allergic asthma

Simvastatin clinically beneficial for PCOS

FR-167356's potential for clinical application in osteoporosis

Phase I data on teverelix for reproductive use

Ghrelin: a novel therapeutic approach for COPD-associated cachexia

Havrix approved for children aged 12 months and older

Allos withdraws Revaproxyn MAA in Europe

Approvable letter for Pargluva

Long-lasting responses to rituximab seen in pemphigus patients / News in Context

Pegaptanib beneficial in early age-related macular degeneration

Metastatic melanoma responses seen with anti-CTLA-4 antibody and peptide vaccine

New agents for treating obesity disclosed in recent AstraZeneca patent

Novel antidiabetic agents reported in recent patent literature

Novel treatment options for hepatitis C imparted in recent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.